Epizyme, Inc. (NASDAQ:EPZM) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Monday, November 6th.
A number of other analysts also recently issued reports on EPZM. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, July 12th. BidaskClub downgraded Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Royal Bank Of Canada set a $20.00 price objective on Epizyme and gave the stock a “buy” rating in a research note on Saturday, August 5th. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a report on Monday, August 7th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $28.00 target price (down previously from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. Epizyme has a consensus rating of “Buy” and a consensus price target of $22.67.
Epizyme (EPZM) traded down $0.80 during trading hours on Monday, reaching $11.90. The company’s stock had a trading volume of 521,744 shares, compared to its average volume of 462,646. Epizyme has a 1-year low of $9.30 and a 1-year high of $20.45.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the transaction, the insider now owns 23,123 shares in the company, valued at approximately $380,142.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David M. Mott acquired 200,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the acquisition, the director now owns 6,000 shares in the company, valued at $91,500. The disclosure for this purchase can be found here. 25.20% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc boosted its holdings in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 795 shares during the period. UBS Asset Management Americas Inc. purchased a new position in Epizyme during the 1st quarter valued at $175,000. Fox Run Management L.L.C. purchased a new position in Epizyme during the 3rd quarter valued at $223,000. BB&T Securities LLC purchased a new position in Epizyme during the 2nd quarter valued at $181,000. Finally, Trexquant Investment LP purchased a new position in Epizyme during the 2nd quarter valued at $184,000. Institutional investors own 78.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Epizyme, Inc. (NASDAQ:EPZM) Downgraded by ValuEngine to “Sell”” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/epizyme-inc-epzm-cut-to-sell-at-valuengine/1762368.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with our FREE daily email newsletter.